Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell ...

Patients with stage IB to IIIA non-small cell lung cancer that received osimertinib after surgery had a 51% lower risk of death compared to placebo. OS benefit observed across all predefined ...

Adding a mutation-specific targeted drug to osimertinib (Tagrisso) substantially increased the objective response rate (ORR) in newly diagnosed EGFR-mutant, MET-aberrant non-small cell lung cancer ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

CHICAGO — Osimertinib (Tagrisso) may soon have approvals across all stages of epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). The third-generation EGFR ...

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EG ...

Patients with EGFR-mutated NSCLC who received osimertinib had an elevated risk for therapy-related cardiac events. Cardiac events were independently associated with survival. Patients with EGFR ...

Many lung cancer patients now have access to a potentially life-saving medication. Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a ...

(Singapore – 10:05 a.m. SGT--September 11, 2023) – Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared ...

Osimertinib is available in the tablet form to be taken by mouth (orally) once a day with or without food. In case of difficulty in swallowing, disperse the tablet in a glass of 60 mL or 2 ounces ...